Free Trial
NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Price, News & Analysis

Alterity Therapeutics logo
$1.15
-0.03 (-2.54%)
(As of 10/31/2024 ET)

About Alterity Therapeutics Stock (NASDAQ:ATHE)

Key Stats

Today's Range
$1.10
$1.17
50-Day Range
$1.15
$1.55
52-Week Range
$1.01
$5.41
Volume
7,292 shs
Average Volume
45,937 shs
Market Capitalization
$8.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
75th Percentile Overall Score

ATHE MarketRank™: 

Alterity Therapeutics scored higher than 75% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alterity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alterity Therapeutics has received no research coverage in the past 90 days.

  • Read more about Alterity Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Alterity Therapeutics are expected to grow in the coming year, from ($0.25) to ($0.13) per share.

  • Price to Book Value per Share Ratio

    Alterity Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.07% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 36.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Alterity Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Alterity Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the float of Alterity Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alterity Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alterity Therapeutics has recently decreased by 36.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Alterity Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Alterity Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.14% of the stock of Alterity Therapeutics is held by institutions.

  • Read more about Alterity Therapeutics' insider trading history.
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Stock News Headlines

Alterity Therapeutics reports cash balance of A$9.28M as of September 30
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
See More Headlines

ATHE Stock Analysis - Frequently Asked Questions

Alterity Therapeutics' stock was trading at $2.49 on January 1st, 2024. Since then, ATHE shares have decreased by 53.8% and is now trading at $1.15.
View the best growth stocks for 2024 here
.

Alterity Therapeutics shares reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alterity Therapeutics investors own include NVIDIA (NVDA), General Electric (GE), Broadcom (AVGO), Meta Platforms (META), Dorian LPG (LPG), CymaBay Therapeutics (CBAY) and CONSOL Energy (CEIX).

Company Calendar

Today
10/31/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHE
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+247.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.24 per share

Miscellaneous

Free Float
4,471,000
Market Cap
$8.40 million
Optionable
Not Optionable
Beta
0.85
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ATHE) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners